drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (mRNA-engineered TCR-T)
drug_description
Autologous mRNA-engineered TCR-T cell therapy in which a patient’s T cells are transiently transfected with mRNA encoding HBV-specific T-cell receptors; infused cells recognize HBV peptides presented by HLA-A*02:01/A*11:01/A*24:02 on infected hepatocytes and mediate MHC class I–restricted cytotoxicity to reduce HBV-infected cells and antigen burden.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Immunotherapy, Adoptive
drug_category
ENGINEERED TCR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are transiently transfected with mRNA encoding HBV-specific T-cell receptors; after infusion, they recognize HBV peptides presented by HLA-A*02:01/A*11:01/A*24:02 on infected hepatocytes and execute MHC class I–restricted cytotoxicity to reduce HBV-infected cells and antigen burden.
drug_name
LioCyx-M
nct_id_drug_ref
NCT06885710